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ABSTRACT
Objective To examine the evidence on the benefits and
harms of screening for prostate cancer.
Design Systematic review and meta-analysis of
randomised controlled trials.
Data sources Electronic databases including Medline,
Embase, CENTRAL, abstract proceedings, and reference
lists up to July 2010.
Review methods Included studies were randomised
controlledtrials comparingscreeningbyprostate specific
antigen with or without digital rectal examination versus
no screening. Data abstraction and assessment of
methodological quality with the GRADE approach was
assessed by two independent reviewers and verified by
the primary investigator. Mantel-Haenszel and inverse
variance estimates were calculated and pooled under a
random effects model expressing data as relative risks
and 95% confidence intervals.
Results Six randomised controlled trials with a total of
387286 participants that met inclusion criteria were
analysed. Screening was associated with an increased
probability of receiving a diagnosis of prostate cancer
(relative risk 1.46, 95% confidence interval 1.21 to 1.77;
P<0.001) and stage I prostate cancer (1.95, 1.22 to 3.13;
P=0.005). There was no significant effect of screening on
deathfromprostatecancer(0.88,0.71to1.09;P=0.25)or
overall mortality (0.99, 0.97 to 1.01; P=0.44). All trials
had one or more substantial methodological limitations.
None provided data on the effects of screening on
participants’ quality of life. Little information was
provided about potential harms associated with
screening.
Conclusions The existing evidence from randomised
controlled trials does not support the routine use of
screening for prostate cancer with prostate specific
antigen with or without digital rectal examination.
INTRODUCTION
Prostate cancer is the most common non-skin cancer
among men worldwide
1 and, after lung cancer, is the
second leading cause of deaths from cancer in men in
the United States.
2 Screening has been advocated as a
means of detecting prostate cancer in the early stages,
which are amenable to local interventions with
curativeintent,to decreaseoverall anddisease specific
mortality.
3 The benefits and harms of prostate cancer
screening, however, have become the topic of contro-
versy, as reflected by numerous recent editorials,
4-7
position statements, and guidance documents.
8-10
Population based recommendations for cancer
screening should ideally be based on high quality evi-
dence derived from systematic reviews of randomised
controlled trials that document a positive impact of
screening on outcomes that are the most important to
patients.
11 In 2006, a systematic review published in
theCochraneLibraryconcludedthattherewasinsuffi-
cient evidence to either support or refute the routine
use of mass, selective, or opportunistic screening com-
pared with no screening.
12 This Cochrane systematic
review was based on two randomised controlled trials
that enrolled 55512 participants overall but was lim-
ited by substantial methodological weaknesses in the
design, conduct, and analysis of the included studies.
The evidence drawn from this systematic review did
not show that screening improved outcomes. By
2010, four additional trials
413-15 enrolling 351531 par-
ticipantshadbeenpublished,therebyprovidingstrong
impetusforanupdatedsynthesisofresearchevidence.
We performed a systematic review and meta-analy-
sis on the role of screening for prostate cancer to guide
decision making in health policy. Specifically, we
assessed the question of whether in men withouta pre-
vious history of prostate cancer, screening by testing
forprostatespecificantigenwithorwithoutdigitalrec-
tal examination when compared with no screening
affects the two most important outcomes to patients:
overall and disease specific mortality.
METHODS
Data sources and searches
We conducted a systematic search of electronic data-
bases, abstract proceedings of major scientific meet-
ings, and bibliographies of all eligible studies from 1
January 2005 to the present (the last systematic search
was dated 13 July 2010) to identify all relevant studies
since the comprehensive search conducted for the sys-
tematic review published in the Cochrane Library in
2006.
12 Electronic databases searched included
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tryofControlledTrials(CENTRAL).Thesearchstrat-
egy involved combining a methodological filter to
identify randomised controlled trials
16 with subject
specific terms related to screening for prostate cancer
((“Mass Screening”[Mesh] OR “Early Detection of
Cancer”[Mesh]) AND “Prostatic Neoplasms”[Mesh]).
The manual search included abstracts presented at
the American Urological Association (AUA), Eur-
opean Association of Urology (EAU), and American
Society of Clinical Oncology (ASCO) meetings from
2005to2010.Wealsosearchedforadditionalsystema-
tic reviews and narrative reviews on the topic to iden-
tify eligibletrials.Studies were consideredirrespective
of language or publication status. Two independent
reviewers (MD and MMN) performed all aspects of
the search strategy, examined the abstracts of all cita-
tionsforrelevancetoourpredefinedinclusioncriteria,
andreviewedthefulltextarticlesindetailasindicated.
PD reviewed and arbitrated any disagreements.
Study selection
Randomised controlled trials comparing screening of
asymptomatic men for prostate cancer versus no
screening were eligible for inclusion. The screening
interventionwasdefinedastestingforprostatespecific
antigen with or without digital rectal examination. We
did not include trials with participants with previously
diagnosed prostate cancer.
Data extraction and quality assessment
A standardised form was created, piloted, and then
used to abstract the available data for the predefined
outcomes of interest. These were: all cause mortality
and death from prostate cancer, diagnosis of prostate
cancer, effect of screening on stage at diagnosis, false
positive and false negative results, harms of screening,
qualityoflife,andcosteffectiveness.Weusedthe2010
AmericanJointCommitteeonCancersystemforpros-
tate cancer staging.
17 Two authors (MD and MMN)
independently extracted data. Disagreements were
resolved by discussion, consensus, and arbitration by
a third author (PD). Data were extracted on the meth-
odological domains relevant to minimising bias and
random error in the analysis of trials by using the
Cochrane methods for assessing risk of bias
18 and
GRADE methods.
19 Specifically, we assessed study
limitations by evaluating the method of randomisa-
tion, allocation concealment, blinding, analysis by
intention to screen, contamination of the control arm,
and completeness of follow-up. As per GRADE,
19 we
further assessed the quality of evidence with regard to
inconsistency (heterogeneity), indirectness, impreci-
sion, and other potential sources of bias, such as pub-
lication and reporting bias (see below). GRADE
criteria were then applied to downgrade the quality of
evidencewhen indicatedonanoutcomespecificbasis.
Thequalityof evidenceforan individualoutcomewas
ultimately rated as high, moderate, low, or very low.
The review protocol is available from the authors on
request.
Data synthesis and analysis
Relative risks were used to summarise the effect of
screening intervention for all outcomes. Mantel-
Haenszel estimates were calculated based on the num-
ber of events per number of participants in a given
study arm and pooled under a random effects model,
with data expressed as relative risks and 95% confi-
dence intervals. When no information on event rates
was available, we used the inverse variance method.
Heterogeneity was assessed by examining clinical
characteristics of included studies as well as by formal
statisticaltestingwithχ
2andI
2.
18Thepossibilityofpub-
lication bias was assessed with Begg and Egger funnel
plots.
20 The results of these tests are not separately
reported, however, because this method is known to
be unreliable when there are fewer than 10 studies in
the meta-analysis
18 and because our qualitative analy-
sis indicated a high likelihood of reporting bias. Meta-
analysis was performed with RevMan 5
21 according to
the PRISMA guidelines.
22 We used the GRADE
method to summarise findings.
19 We also carried out
predefinedsubgroupanalysesforparticipants’ageand
stage at diagnosis and sensitivity analyses based on
methodological quality parameters.
RESULTS
Systematic review
Thesystematicliteraturesearchidentified493relevant
references (fig 1). After screening titles and abstracts,
weexcluded463non-relevantarticles.The30remain-
ingarticleswereretrievedinfulltextforformalreview.
After independent review, 24 studies were excluded
because they were subset or secondary analyses of
the same trials. We also retrieved recent review
articles,
23 position papers and editorials,
524and a pre-
viously published systematic review,
12 but these did
not yield any additional relevant trials.
Table 1givesdetails ofthe six identifiedstudiesthat
met predefinedinclusionand exclusioncriteria.These
Additional records identified
through other sources (n=104)
Records identified through
database searching (n=389)
Records after duplicates removed (n=493)
Records screened (n=493)
Records excluded (n=463)
Full text articles excluded, with reasons (n=24)
Identification
Screening
Full text articles assessed for eligibility (n=30)
Eligibility
Studies included in qualitative synthesis (n=6)
Studies included in quantitative synthesis (meta-analysis) (n=6)
Included
Fig 1 | Search strategy to identify trials of screening for
prostate cancer
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413-15
enrolled a total of 387286 participants randomised to
eitherprostatecancerscreeningornoscreening.These
trials included the European randomised study of
screening for prostate cancer (ERSPC),
4 the prostate,
lung, colorectal, and ovarian (PLCO) screening
trial,
1425 the French ERSPC,
13 which was part of the
original ERSPC
4 but reported separately, and the
Gothenburg trial,
15 which included participants pre-
viously reported in the ERSPC trial. The Gothenburg
trial
15 enrolled 19904 participants in three birth
cohorts (1930-4, 1935-9, and 1940-4), of which two
(1930-4, 1935-9) were included in the ERSPC
publication
4 as the Swedish cohort (n=11852). Only
the participants of the 1940-4 birth cohort (n=8057)
of the Gothenburg trial
15 represented study partici-
pants not previously reported on. For participants of
the 1930-4 (n=5563) and 1935-9 (n=6284) birth
cohorts, the Gothenburg trial
15 provided longer fol-
low-up than previously reported in the ERSPC.
4 We
included these data in the analyses by excluding the
corresponding participants from the ERSPC.
4
All but one study included measurement of prostate
specific antigen as a screening test in all participants;
theNorrkopingstudy
2627initiallyusedonlydigitalrec-
tal examination but then used a combination of pros-
tate specific antigen and digital rectal examination.
Three of the six studies did not consistently use digital
rectal examination in all participants; in the ERSPC
thescreeningmethoddifferedbyparticipatingcountry
and was mostly based on prostate specific antigen.
4 In
the French ERSPC, only prostate specific antigen test-
ing, not digital rectal examination, was used.
13 Finally,
in the Gothenburg study screening was based on
prostatespecificantigentestingalone,andparticipants
received a digital rectal examination only if the test
result was abnormal.
15
Four studies provided information on all cause
mortality,
414152627five studies on deaths from prostate
cancer,
4141526-30 and five studies on diagnosis of pros-
tate cancer.
413-152627 Length of follow-up ranged from
aboutfourto15years.
1326AllbuttheQuebecstudy
28-30
and the Gothenburg study
15 provided usable informa-
tion on cancer stage at diagnosis. The ERSPC study
4
and, to a limited extent, the Gothenburg study
15
allowed subgroup analyses for death from prostate
cancer based on age groups, but only the Gothenburg
study provided age specific information for all cause
mortality.
15 There were no major discrepancies
between reviewers with regard to trial inclusion or
data extraction. Minor discrepancies in extraction of
clinical characteristics were resolved by consensus
and arbitration by a third independent reviewer (PD).
Assessment of quality of evidence
Common study limitations included inadequate ran-
domisationandallocationconcealment,non-reporting
ofstudywithdrawalsandparticipantslosttofollow-up,
lack of blinding of outcome assessor, contamination,
and failure to perform an intention to treat analysis
(table 1). These prompted downgrading of the overall
qualityofevidenceforallindividualoutcomes(table 2).
Failure of studies that reported on death from prostate
cancer to provide information on all cause mortality
raised further concerns about reporting bias. The evi-
denceondiagnosisofprostatecanceroverallanddiag-
nosisofstagesIandIIprostatecancerwasdowngraded
for inconsistency. For the diagnosisof stage II prostate
Table 1 |Characteristics and methodological quality of randomised controlled trials of screening for prostate cancer
Study
No of participants
randomised
Age range
(years)
Screening
test
Random-
isation
Allocation
concealment
Description
of loss to
follow-up
Blinding of
outcome
assessors
Contamination
(of control
group)
Intention to
screen
analysis
Approximate
median
follow-up time
(years)
Screened
group
Control
group
Quebec
28-30 31 133 15 353 45-80 PSA + DRE Adequate Not
adequate*†
No Notadequate‡ Not provided§ Not analysed
but data
provided
11
Norrkoping
2627 1494 7532 50-69 DRE initially;
PSA + DRE
after 1993
Quasi-
random-
isation**
Notadequate* Yes Notadequate‡ Not provided†† Yes 13 (diagnosis),
15 (death)
ERSPC
4 72 890‡‡ 89 353‡‡ 55-69 PSA + DRE Adequate Not
adequate*†
Unclear§§ Yes Yes (20%) Yes 9
FrenchERSPC
13 42 590 42 191 55-69 PSA Unclear*** Unclear* Unclear§§ Unclear*** Unclear*** Unclear*** 4
PLCO
14 38 343 38 350 55-74 PSA+DRE Adequate Adequate Yes Yes Yes (40-52%) Yes 11.5
Gothenburg
15 9952 9952 50-64 PSA Adequate Not
Adequate†
Yes Yes “Low,”detailsnot
provided
Yes 14
PSA=prostate specific antigen
DRE=digital rectal examination.
*Not reported/could not be assessed (adequacy of allocation concealment could not be deduced from available reports).
†Participants randomised to screening versus control before formal study enrolment, thus raising possibility of selection bias.
‡Cause of death determined based on registry data.
§Study reported that contamination rate could not be assessed.
**Every sixth man from list of dates of birth assigned to screening.
††Contamination rate with respect to control group not provided.
‡‡Number of participants includes 1930-4 and 1935-9 birth cohorts (age 60-64 and 55-59 at randomisation, respectively) of Gothenburg study.
§§No data provided on completeness of follow-up or could not be assessed.
***Could not be assessed or not reported.
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effect size, which included both appreciable benefit
and harm and led to further downgrading for impreci-
sion.Overall,thequalityofevidencewasratedasmod-
erate for both all cause mortality and death from
prostate cancer (table 2).
19
Quantitative assessment
All cause mortality
Four trials that included 256019 randomised partici-
pants contributed information on all cause
mortality.
414152627 As event rates were not available
in all studies, we used the inverse variance method to
pool data from individual trials, resulting in a relative
risk of 0.99 (95% confidence interval 0.97 to 1.01;
P=0.44; fig 2). There was no significant heterogeneity
amongthesetrials(I
2=0%,χ
2=1.89;P=0.60).Asitisnot
plausible that authors would report data on cause spe-
cificmortalitywithouthavingcollecteddataonoverall
mortality we suspect outcome reporting bias
19 for the
Quebec trial.
28-30
Death from prostate cancer
Data on deaths from prostate cancer were available
from five randomised controlled trials.
414152628 The
analysis included 302500 randomised participants.
With the inverse variance method, the calculated rela-
tiveriskwas0.88 (0.71to 1.09;P=0.25) whenanalysed
inanintentiontoscreenanalysis(fig2).Therewascon-
siderable heterogeneity among these trials (I
2=55%,
χ
2=8.89; P=0.06).
Prostate cancer diagnosis
Five trials contributed information on diagnosis of
prostate cancer in 340800 randomised
participants.
413-152627 The Quebec study did not report
ondiseasestagesinthecontrolarm.Therewere10328
men with a diagnosis of prostate cancer among the
159372 men enrolled in the screening group com-
pared with 7968 in the 181428 controls, resulting in a
relative risk of 1.46 (1.21 to 1.77; P<0.001; fig 3) in
favourofscreening.Therewasahighdegreeofhetero-
geneity in these trials (I
2= 97%, χ
2=126.69; P<0.001).
ThesubgroupanalysisforstageIprostatecancerwas
based on 3789 men with a diagnosis of stage I prostate
cancer among the 155317 men in the screening group
compared with 1971 in the 177426 control group,
resulting in a relative risk of 1.95 (1.22 to 3.13;
P=0.005) in favour of screening (fig 4). There was a
high degree of heterogeneity (I
2=96%, χ
2=79.32;
P<0.001).
StageIIprostatecancerwasdiagnosedin5114ofthe
155317 men in the screening group and 4035 of the
177426 controls, resulting in a relative risk of 1.39
(0.99 to 1.95; P=0.05; fig 4). In this analysis, there was
significant heterogeneity (I
2= 97%, χ
2=114.38;
P<0.001).
Table 2 |Summary of findings in trials on screening for prostate cancer
Outcomes
Illustrative comparative risks* (95% CI)
Relative risk (95% CI) No of participants Qualityofevidence(GRADE)†
Event rate (per 1000)
without screening
Event rate (per 1000)
with screening
All cause mortality (inverse variance) 200‡ 198 (194 to 202) 0.99 (0.97 to 1.01) 256 019
41 41 52 6 Moderate
Death from prostate cancer (inverse variance) 8‡ 7 (6 to 9) 0.88 (0.71 to 1.09) 302 500
41 41 52 62 8 Moderate
Prostate cancer diagnosis 44 64 (53 to 78) 1.46 (1.21 to 1.77) 340 800
41 3 - 1 52 6 Low
Effects of screening on stage:
Stage I 11 21 (13 to 34) 1.95 (1.22 to 3.13) 332 743
41 31 42 6 Low
Stage II 23 32 (23 to 45) 1.39 (0.99 to 1.95) 332 743
41 31 42 6 Very low
Stages III-IV 5 5 (4 to 5) 0.94 (0.85 to 1.04) 332 743
41 31 42 6 Moderate
*Event rate in no screening arm is mean risk in control groups across studies. Event rate in screening arm (and its 95% confidence interval) is based on assumed risk in comparison group
and relative effect (relative risk) of intervention (and its 95% CI).
†High quality=further research is very unlikely to change our confidence in the estimate of effect; moderate quality=further research is likely to have an important impact on our confidence
in the estimate of effect and may change the estimate; low quality=further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate; very low quality=we are very uncertain about the estimate.
‡Event rates not available in all trials; representative rates in control arms are based on Gothenburg trial; inverse variance method used to pool data from individual trials.
All cause mortality
  ERSPC 2009
  Gothenburg 2010
  Norrkoping 2004
  PLCO 2009
Total (95% CI)
Test for heterogeneity: τ2=0.00, χ
2=1.89,
  
Test for overall effect: z=0.76, P=0.44
Death from prostate cancer
  ERSPC 2009
  Gothenburg 2010
  Norrkoping 2004
  PLCO 2009
  Quebec 2004
Total (95% CI)
Test for heterogeneity: τ2=0.03, χ
2=8.89,
  
Test for overall effect: z=1.16, P=0.25
df=3, P=0.60, I2=0%
  df=4, P=0.06, I
2=55%
0.99 (0.97 to 1.02)
1.05 (0.94 to 1.18)
1.15 (0.82 to 1.62)
0.98 (0.93 to 1.04)
0.99 (0.97 to 1.01)
0.84 (0.70 to 1.01)
0.56 (0.39 to 0.81)
1.04 (0.64 to 1.68)
1.14 (0.76 to 1.70)
1.01 (0.76 to 1.34)
0.88 (0.71 to 1.09)
80
4
0.4
16
100
30
18
13
16
23
100
0.01 0.1 1 10 100
Favours
screening
Favours
control
Risk ratio IV,
random (95% CI)
Risk ratio IV,
random (95% CI)
Weight
(%)
-0.01 (0.01)
0.05 (0.06)
0.14 (0.17)
-0.02 (0.03)
-0.17 (0.09)
-0.58 (0.19)
0.04 (0.25)
0.13 (0.21)
0.01 (0.14)
Log[risk ratio]
(SE)
Fig 2 | Effects of screening on all cause mortality and death from prostate cancer
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cancer were based on 332743 randomised partici-
pants. Stages III and IV cancer were diagnosed in
701 of 155317 men enrolled in the screening group
and 975 of 177426 controls, resulting in a relative
risk of 0.94 (0.85 to 1.04; P=0.22; fig 4). There was no
significant heterogeneity in this analysis (I
2=0%,
χ
2=1.22; P=0.75).
Subgroup analysis based on age
Age specific information for all cause mortality was
limited to the Gothenburg study,
15 which reported
relative risks of 1.05 (0.94 to 1.18), 0.99 (0.90 to 1.09),
and 0.99 (0.91 to 1.07) for participants aged 50-54, 55-
59, and 60-64, respectively. Data on the effect of
screening on death from prostate cancer were largely
limited to the ERSPC,
4 with additional information
from the Gothenburg study
15 only for men aged 50-
54. The relative risks of death from prostate cancer in
the screening compared with the control arms for par-
ticipants aged 50-54, 55-59, 60-64, 65-69, and 70-74
were 0.90 (0.39 to 2.10), 0.73 (0.53 to 1.00), 0.94 (0.69
to 1.27), 0.74 (0.56 to 0.99), and 1.26 (0.80 to 1.99),
respectively.
Limited information on age specific diagnosis of
prostate cancer based on digital rectal examination
alonewasavailablefromthefirsttwoscreeningrounds
of the Norrkoping study.
27 In addition, the Gothen-
burg study contributed data based on prostate specific
antigentestingformenaged50-54,55-59,and60-64.
15
The relative risks for a diagnosis of prostate cancer in
the screening compared with the control arms for par-
ticipantsaged50-54,55-59,60-64,and65-69were1.81
(1.53to2.13),1.62(1.40to1.88),1.38(1.19to1.61)and
2.44 (1.41 to 4.25), respectively.
Other outcomes
The randomised controlled trials we included failed to
reportcomplicationsratesinthescreeningandcontrol
group so we could not quantitatively pool data. The
ERSPC trial did not include updates on the adverse
events it reported in 2002.
3132 A recent abstract based
on three ERSPC centres reported no excess mortality
associated with prostate biopsies in the screening
arm.
33 The PLCO trial reported that digital rectal
examination led to bleeding or pain at a rate of 0.3 per
10000screenings,andtheprostatespecificantigentest
included three episodes of fainting per 10000
screenings.
14 Medical complications (such as infec-
tions,bleeding,clotformation,andurinarydifficulties)
occurred in 68 per 10000 diagnostic evaluations. No
other studies reported data in either a qualitative or
quantitative format. The Norrkoping study
26 and the
ERSPC
4 reported false positive rates with screening
of 82.5% and 75.9%, respectively, asverified by subse-
quentprostatebiopsy.Nostudyreporteddataonqual-
ity of life. Though the ERSPC study collected data on
quality of life, no detailed analyses have been made
available to date.
The Norrkoping study reported that screening costs
inthe1990swere£1640perdetectedcancerand£2343
perdetectedandcuredcancer.
27Inlightofourfindings
indicating no effect of screening on survival—that is,
improvement in cure rates—these cost effectiveness
results do not seem plausible. No other study reported
data on costs or cost effectiveness.
DISCUSSION
Main findings
In this systematic review and meta-analysis of prostate
cancer screening we failed to find a significant impact
of prostate cancer screening on overall mortality or
death from prostate cancer, the most critical outcomes
  PLCO 2009
  French ERSPC 2009
  Norrkoping 2004
  ERSPC 2009
  Gothenburg 2010
Total (95% CI)
Test for heterogeneity: τ2=0.04, χ
2=126.69,
  
Test for overall effect: z=3.85, P<0.001
df=4, P<0.001, I2=97%
1.21 (1.15 to 1.28)
1.24 (1.14 to 1.36)
1.47 (1.16 to 1.86)
1.70 (1.64 to 1.77)
1.81 (1.54 to 2.13)
1.46 (1.21 to 1.77)
22
21
17
22
19
100
0.01 0.1 1 10 100
Favours
control
Favours
screening
Risk ratio
random (95% CI)
Risk ratio
random (95% CI)
Weight
(%)
Prostate cancer
diagnosis
2820/38 343
1053/42 590
85/1494
5990/72 890
380/4055
10 328/159 372
Screening
2322/38 350
840/42 191
292/7532
4307/89 353
207/4002
7968/181 428
Control
No of events/total
Fig 3 | Effects of screening on diagnosis of prostate cancer
Stage I
  ERSPC 2009
  French ERSPC 2009
  Norrkoping 2004
  PLCO 2009
Total (95% CI)
Test for heterogeneity: τ2=0.20, χ2=79.32,
  
Test for overall effect: z=2.80, P=0.005
Stage II
  ERSPC 2009
  French ERSPC 2009
  Norrkoping 2004
  PLCO 2009
Total (95% CI)
Test for heterogeneity: τ2=0.10, χ
2=114.38,
  
Test for overall effect: z=1.93, P=0.05
Stage III and IV
  ERSPC 2009
  French ERSPC 2009
  Norrkoping 2004
  PLCO 2009
Total (95% CI)
Test for heterogeneity: τ2=0.00, χ2=1.22,
  
Test for overall effect: z=1.23, P=0.22
2.59 (2.44 to 2.74)
1.33 (1.16 to 1.53)
3.15 (2.13 to 4.66)
1.20 (0.60 to 2.38)
1.95 (1.22 to 3.13)
1.96 (1.81 to 2.12)
1.32 (1.08 to 1.61)
1.15 (0.72 to 1.84)
1.18 (1.13 to 1.24)
1.39 (0.99 to 1.95)
0.94 (0.83 to 1.05)
1.21 (0.76 to 1.93)
0.92 (0.60 to 1.41)
0.90 (0.71 to 1.15)
0.94 (0.85 to 1.04 )
29
29
24
18
100
28
26
18
28
100
74
4
5
16
100
0.01 0.1 1 10 100
Favours
control
Favours
screening
Risk ratio
random (95% CI)
Risk ratio
random (95% CI)
Weight
(%)
3276/72 890
455/42 590
40/1494
18/38 343
3789/155 317
1571/72 890
225/42 590
21/1494
3297/38 343
5114/155 317
516/72 890
39/42 590
24/1494
122/38 343
701/155 317
Screening
1553/89 353
339/42 191
64/7532
15/38 350
1971/177 426
984/89 353
169/42 191
92/7532
2790/38 350
4035/177 426
676/89 353
32/42 191
132/7532
135/38 350
975/177 426
Control
No of events/total
df=3, P<0.001, I2=96%
df=3, P<0.001, I
2=97%
df=3, P=0.75, I
2=0%
Risk ratio
random (95% CI)
Weight
(%)
Screening Control
Fig 4 | Effects of screening on prostate cancer stage at time of diagnosis
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death from prostate cancer was of moderate quality
according to the GRADE approach. In contrast,
based on low quality evidence, screening was asso-
ciatedwitha46%relativeincreaseindiagnosesofpros-
tate cancer in the screening arm compared with no
screening. A predefined subgroup analysis based on
disease stage indicated that this relative increase was
attributable mainly to an increase in the number of
men diagnosed with stage I prostate cancer. There
wasnosignificantimpactofscreeningonthediagnosis
ofstage IIandstages IIIandIV prostatecancer.These
findings suggest that screening leads to an increase in
diagnosis of early stage prostate cancer that does not
seem to translate into a benefit in overall survival and
survival specific to prostate cancer. On average, 20
more men will be detected with prostate cancer (95%
confidenceinterval9to34)per1000patientsscreened.
The finding that an increased rate of diagnosis fails to
translate into improved overall and disease specific
mortality rates is probably multifactorial and relates
in part to the prolonged and relatively slow natural
course in many patients, particularly those with low
grade prostate cancer.
3435 Our results confirm pre-
viously voiced concerns about overdiagnosis of pros-
tatecancer
67232436—thatis,detectionofcancerthatwill
not negatively affect survival. These findings are sup-
portedbystudiesthathaveusedstatisticalmodellingof
populationbaseddatafromatumourregistry
37andthe
ERSPCstudy
3839andfoundoverdiagnosisratesof29%
and 56%, respectively.
Strengths and limitations
We included the new evidence provided by the publi-
cation of the PLCO,
14 ERSPC,
4 and French ERSPC
13
as well as the Gothenburg trial.
15 These recently pub-
lished randomised controlled trials conducted in the
US and Europe included over 350000 participants,
representing major international efforts to address the
controversy surrounding prostate cancer screening.
Our systematic review, which includes these studies,
therefore reflects the current best evidence on which
decision making on health policy should be based.
Weratedthemethodologicalqualityandriskofbias
in studies meeting predefined inclusion and exclusion
criteria using the GRADE approach. Limitations of
ourstudyrelatetothequalityandquantityoftheavail-
able evidence on this topic. Unearthing the limitations
in the evidence base, however, is as important as the
overallfindingsrelatedtotheeffectsofscreening.Con-
sidering the tremendous impact of decisions for or
against prostate cancer screening on health policy, it
is surprising that few randomised controlled trials
have examined this issue with sufficient rigor.Existing
studies have considerable methodological shortcom-
ings that resulted in downgrading of the quality of evi-
dence from high to moderate for all cause mortality
and disease specific mortality (critical outcomes) and
fromhightolowqualityevidencefordiagnosisofpros-
tate cancer (important outcome), as well as consider-
able inconsistency. Most of the potential biases
identifiedintheindividualtrials(suchaslackofalloca-
tionconcealmentorintentiontoscreenanalysis)would
be expected to favour the screening arm. On the other
hand, contamination of the non-screening arm, a pos-
sible issue in all studies and one that was explicitly
reported as being a major issue in the PLCO study,
potentiallyintroducedabiastowardsnotfindingaben-
efit of screening.
23 Another limitation of the available
evidence relates to the short length of follow-up of
reported studies. Assuming an estimated lead time
bias of five and a half to seven years, follow-up might
not have been long enough to detect differences in
mortality given the low number of deaths from pros-
tate cancer.
39 Lastly, there was insufficient evidence to
analyse the impact of screening on high risk popula-
tions, such as patients with a strong family history of
prostate cancer or African-Americans.
One of our predefined objectives was the analysis of
the effect of screening interventions based on partici-
pants’ age. This analysis was limited by the lack of
available data beyond those provided by the ERSPC
study,
4theGothenburgstudy,
15andtheearlyphasesof
the Norrkoping study.
2627 As none of the studies used
age as a stratification factor for randomisation, these
subgroup analyses should be interpreted with
caution.
40 Our analysis failed to show a clinically
important benefit of screening on death from prostate
cancer in any of the age groups. The US Preventive
Services Task Force advises against routine prostate
cancer screening in patients of age 75 and older to
avoid unnecessary testing and overtreatment.
41
Indeed, according to the ERSPC
4 study, prostate can-
cer screening in men aged 70-74 was associated with a
relativeriskofdeathfromprostatecancerof1.26witha
wide 95% confidence interval from 0.80 to 1.99. In
terms of relative risk, this could mean either a 20%
reduced or about 100% increased risk, therefore cau-
tionisjustifiedwhenrecommendingroutinescreening
inthispopulation.Oursystematicreviewindicatesthat
similarrestraintsmightbeindicatedforroutinescreen-
ing in all age groups.
Comparison with other reviews
Our review differs from the previously published
Cochrane review
12 in that it includes a total of
387286 participants and provides a relatively precise
estimate of the impact of prostate cancer screening on
overall mortality with modest quality of evidence.
Based on this analysis, it seems unlikely that future
large trials in similar populations of participants with
digital rectal examination and testing for prostate spe-
cific antigen in a screening setting will yield divergent
results. In contrast, the confidence interval surround-
ing the pooled point estimate for death from prostate
cancerincludesbotha29%relativereductionaswellas
a 9% relative increase in risk of death secondary to
prostate cancer. If we assume an average event rate of
deathfromprostatecancerof0.78%,asobservedinthe
control arm of the Gothenburg study,
15 screening of
10000 men would be expected to result in about 22
fewer to seven more deaths related to prostate cancer.
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(and potential future trials if funded and executed)
could help to further characterise the actual effect of
screening for prostate cancer on disease specific mor-
tality, our findings suggest that the expected impact in
absolute terms would be modest at best.
Study implications
Our study highlights the complexities of the contro-
versy over prostate cancer screening, in particular
those of overdiagnosis and the poorly quantifiable
downstream harms of overtreatment and impact on
quality of life that none of the existing trials has ade-
quately addressed. Accurate estimates of rates of over-
diagnosis are challenging, requiring studies with
sufficiently long term follow-up data, a criterion not
met by any of the available trials on prostate cancer
screening, as well as modelling the natural course of
prostate cancer, the impact of early diagnosis, and the
role of competing mortality.
36 Our systematic review
based on all the available evidence failed to show a
significant impact of screening on all cause mortality
or disease specific mortality. These findings suggest
that the rate of overdiagnosis corresponds to the rate
of diagnosis of prostate cancer in the screening group
compared with the control group.
This study further identifies the challenges faced by
future clinical trials. These include the choice of the
appropriate screening threshold and interval, the
issueofcontaminationbetweenthescreeningandcon-
trol arm, and compliance with recommendations for
biopsy. Each of these factors differed considerably
between the two major ERSPC and PLCO studies
and probably contributed to their different
outcomes.
42 It is also noteworthy that these two trials
published their results for different reasons. Whereas
the ERSPC was published after its third interim analy-
sis showed a significant benefit in favour of screening,
the PLCO study was stopped over concerns of poten-
tial harm.
42
Several related studies are ongoing and expected to
provide further evidence on the benefits and harms of
screening as well as the effect of subsequent treatment
choices in patients with positive results. The prostate
testing for cancer and treatment (ProtecT) trial in the
UnitedKingdom
4344anditsextension,thecomparison
arm for ProtecT (CAP) trial,
45 are ongoing but not
expected to report their final results until 2013 and
2015, respectively. This cluster randomised trial has
allocated practices with about 460000 men aged 50-
69 to either usual care or population based screening
with prostate specific antigen (biopsy if prostate speci-
fic antigen ≥3 ng/ml) followed by randomisation of
participants diagnosed with prostate cancer (about
1500 expected) to either radical surgery, conformal
radiotherapy, or active surveillance. In the US, from
1994 to 2002 the prostate cancer intervention versus
observation trial (PIVOT) randomised 731 men from
an ethnically diverse background to either radical
prostatectomy or active surveillance.
46 Reporting of
the final results is expected within the next one to two
years. Lastly, the surveillance therapy against radical
treatment (START) trial is an ongoing study based in
Canada that is planning to randomise 2130 men with
lowrisklocalisedprostatecancertoactivesurveillance
versusearlyinterventionswithcurativeintent.
47These
trials, along with the complete follow-up and full
reporting of the PLCO trial,
14 ERSPC,
4 French
ERSPC,
13andGothenburgtrial,
15willcontributeaddi-
tional valuable information to our knowledge about
thebenefitsandharmsofscreeningforprostatecancer.
In summary, existing evidence from randomised
controlled trials does not support the routine use of
screening for prostate cancer, though screening prob-
ably aids in earlier diagnosis and helps to detect pros-
tate cancer at an earlier stage. This early detection,
which has not been shown to have a significant impact
on mortality, comes at the price of additional testing,
the risk of overtreatment and downstream adverse
effects, and impaired quality of life that currently can-
not be precisely quantified. Patients need to be
informed about the existing uncertainties; individual
patients’ values and preferences are key factors in
deciding whether to offer screening.
4144346At the indi-
vidual level, it is conceivable that some patients would
valueearlydetection,whileothersmightwanttoavoid
the risk of overdiagnosis. Until further evidence accu-
mulates, this systematic review should serve as a basis
forthedevelopmentofevidencebasedclinicalpractice
guidelines by relevant stakeholder organisations and
prompt an update of such guidelines that continue to
actively promote routine prostate cancer screening
48
even in the absence of reliable evidence, as reflected
by our study findings.
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